Psychedelics for Treating Mental Disorders | Dr. Matthew Johnson
Huberman Lab Podcast Recap
Published:
Duration: 3 hr 33 min
Guests: Dr. Matthew Johnson
Summary
Dr. Matthew Johnson, a professor at Johns Hopkins University, discusses the potential of psychedelics like psilocybin and LSD in altering brain chemistry to treat mental disorders such as depression and PTSD. He highlights both the therapeutic benefits and the risks involved in psychedelic...
What Happened
Dr. Matthew Johnson, a renowned professor at Johns Hopkins University, leads research on the therapeutic use of psychedelics such as psilocybin and LSD. These substances can alter neural circuitry, offering potential treatments for mental disorders like depression and PTSD. Dr. Johnson's work has gained prominence through features in major publications and media.
Classic psychedelics like LSD, psilocybin, DMT, and mescaline act on the serotonin 2A receptor, while other compounds like ketamine work as NMDA antagonists. The therapeutic use of these substances often involves guiding patients through altered states of consciousness, which can include hallucinations and changes in perception of time and space.
Psilocybin, administered in clinical trials as a pure compound, is typically dosed between 5 and 30 milligrams. These sessions aim to create meaningful experiences without cognitive tests, focusing instead on emotional exploration. Patients are encouraged to 'let go' and explore their thoughts and feelings, a process akin to trust in psychotherapy.
The therapeutic effects of psychedelics involve changes in self-representation and reality perception, sometimes leading to lasting behavioral changes. For instance, users have reported quitting smoking after psychedelic experiences. The therapy emphasizes a safe and supportive environment to enable deep introspection and personal growth.
Dr. Johnson addresses the risks associated with psychedelics, such as their potential destabilization in individuals with severe psychiatric illnesses. The structured use in clinical settings minimizes these risks, and research often excludes those with a family history of psychotic disorders.
Microdosing, or taking sub-hallucinogenic doses of psychedelics, is a growing trend believed to enhance focus and mood. However, Dr. Johnson notes the lack of substantial peer-reviewed evidence supporting its benefits, with some studies indicating slight impairments instead.
Legal and regulatory landscapes are evolving, with Oregon legalizing psilocybin therapy and MDMA expected to gain FDA approval for PTSD treatment. Despite federal restrictions, the psychedelic movement continues to grow, supported by private philanthropy and significant interest from industries like sports.
Dr. Johnson's ongoing research includes studies on opioid addiction, PTSD, and the use of LSD for chronic pain. His work is supported by organizations like the Heffter Research Institute and the Beckley Institute, which play a critical role in advancing psychedelic research.
Key Insights
- Dr. Matthew Johnson's research at Johns Hopkins University highlights how psychedelics like psilocybin and LSD can alter neural circuitry, potentially treating mental disorders such as depression and PTSD. These substances act primarily on the serotonin 2A receptor, leading to altered states of consciousness.
- In therapeutic settings, psilocybin is administered as a pure compound, often in doses adjusted for body weight. These sessions focus on creating meaningful experiences that encourage emotional exploration, without the distraction of cognitive tasks.
- Microdosing psychedelics is a popular trend, with claims of improved focus and mood. However, there is limited peer-reviewed evidence to support these claims, and some studies suggest potential impairments rather than benefits.
- The legal status of psychedelics in the US is complex, with some states like Oregon legalizing psilocybin therapy. MDMA is on track for FDA approval for PTSD treatment, reflecting a growing interest and acceptance of psychedelics in therapeutic contexts.